The common apolipoprotein A-1 polymorphism −75A>G is associated with ethnic differences in recurrent coronary events after recovery from an acute myocardial infarction by Block, Robert et al.
Heart International 2009; volume 4:e8
Abstract 
Since  data  regarding  the  relationship
between a common polymorphism (SNP) of the
apoA1 gene with apoA1 levels and risk of coro-
nary  artery  disease  are  inconsistent,  we
hypothesized  that  its  association  with  recur-
rent coronary events differs for White and Black
individuals with diagnosed coronary heart dis-
ease. The apoA1 -75G>A SNP was genotyped in
a  cohort  of  834  Black  (n=129)  and  White
(n=705)  post-myocardial  infarction  patients.
Recurrent  coronary  events  (coronary-related
death,  non-fatal  myocardial  infarction,  or
unstable angina) were documented during an
average follow-up of 28 months. Thirty percent
of White and 21% of Black patients carried the
SNP.  Cox  proportional-hazards  regression
analysis, adjusting for clinical and laboratory
covariates, demonstrated that the SNP was not
associated with recurrent events in the total
cohort (HR=1.37, 95% CI 0.95-1.97; p=0.09) but
was  the  only  variable  associated  with  an
increased risk of recurrent cardiac events in
Blacks (HR=2.40, 95% CI 1.07-5.40; p= 0.034).
Conversely in Whites, the SNP was not associ-
ated with recurrent events (HR=1.12, 95% CI
0.75-1.67;  p= 0.59)  whereas  apoB  (HR=1.78,
95% CI 1.20 -2.65; p=0.0042) and calcium chan-
nel  blocker  use  (HR=2.53,  95%  CI  1.72-3.72;
p<0.001) were associated; p=0.0024 for inter-
action between ethnicity and the SNP. A com-
mon apoA1 SNP is associated with a signifi-
cantly  increased  risk  of  recurrent  cardiac
events  among  Black,  but  not  White,  post-
myocardial infarction  patients. Relationships
with lipoproteins may help explain this finding. 
Introduction
Apolipoprotein  A-1  (apoA1)  is  the  major
surface  protein  constituent  of  high-density
lipoprotein  cholesterol  (HDL-C)  and  plays  a
vital role in lipid transport and metabolism.
1
A low level of high density lipoprotein cho-
lesterol (HDL-C) is an established risk factor
for cardiovascular disease 
2 and low levels of
apoA1 have been linked to a wide variety of
cardiovascular events.
3 Low ApoA1 levels have
also  been  associated  with  carotid  intima
media  thickness  (CIMT)  in  a  cohort  of
Swedish men
4 and in the Atherosclerosis Risk
in  Communities  Study  low  levels  of  apoA1
were  associated  with  CIMT  in  men  and
women.
5
ApoA1 polymorphisms have been reported
on the long arm of chromosome 11, including
the -75G>A variant in which guanine (G) is
substituted  by  adenine  (A).
6 This  particular
variant  occurs  frequently  in  Caucasians.
6 In
healthy  individuals,  this  variant  has  been
associated with increased transcription of the
apoA1 gene and higher circulating levels of
HDL-C and apo  A1 in some studies
7-10 but not
in  others.
11,12 These  conflicting  data  may  be
due to the fact that this polymorphism was
evaluated in mixed ethnic groups and, there-
fore,  we  sought  to  determine  whether  the
apoA1  -75G>A polymorphism  is  associated
with cardiovascular events in post-myocardial
infarction (MI) patients and whether ethnici-
ty influences the association. If the polymor-
phism increases risk in only one ethnic group,
this may have implications for risk stratifica-
tion and in the design of therapeutics.
Materials and Methods
Study population 
The THROMBO Study was a prospective,
multicenter  investigation  that  enrolled
patients  with  acute  myocardial  infarction
(MI) from 13 participating hospitals in the
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United States between October 1, 1994, and
June 30, 1997.
13 A total of 1,161 patients were
enrolled  at  the  time  of  hospital  discharge.
Blood samples for genetic analysis were col-
lected at study enrollment from 1,012 of the
recruited patients. The average follow-up was
28  months.  The  details  of  this  study  have
been reported in the primary publication, and
the clinical parameters that defined this study
population included a full spectrum of tradi-
tional post-infarction risk factors. The study
was composed mainly of 3 self-reported eth-
nic  populations:  Blacks  (n=145),  Latinos
(n=81),  and  Whites  (n=771)  living  in  the
United  States;  other  populations  including
Asian or Pacific Islanders, American Indians,
native Alaskans, and Indians composed a rel-
atively  small  proportion  of  study  patients
(n=15).  In  the  current  study,  we  compared
the  clinical  course  of  Black  (n=129)  and
White (n=705) patients for whom follow-up
data  were  available  beginning  two  months
after their index event. Demographic infor-
mation and medical history were obtained on
enrollment in the trial, and medication usage
was  recorded  during  the  baseline  visit  two
months after the index MI. Ejection fraction
was  determined  by  an  echocardiogram,  a
nuclear study, or angiography during the ini-
tial hospitalization after the MI. This study
was approved by institutional review boards
for human subjects at all participating insti-
tutions. 
End point 
The pre-specified coronary event end point
was first occurrence of death from coronary
heart disease, enzyme-documented non-fatal
MI, or hospitalization for unstable angina. A
2-member  committee  categorized  the  coro-
nary events from appropriate medical records
according to pre-specified written criteria, as
previously  described.
13 The  risk  of  the  end
point was assessed by ethnicity and stratified
by the presence of the 75G>A mutation (GG
genotype carriers vs. AG or AA genotype carri-
ers). 
Laboratory methods 
Biochemical measurements 
Blood was drawn in the fasting state at the
baseline  clinic  visit  two  months  after  the
index  MI.  Plasma  and  serum  samples  were
each separated, frozen, and sent to Rochester,
NY, for central storage in a freezer at -70°C.
Biomarker  measurements  were  conducted
using standard methods described in the par-
ent study publication.
13
Genotyping 
Buffy  coats  were  isolated  and  stored  at 
-70°C  until  extracted  for  DNA  analysis.
Genotyping was performed through a contrac-
tual  agreement  with  Millennium  Pharma-
ceuticals. The apoA1 (75G>A) polymorphism
(refSNP  ID  rs670)  was  typed  using  the
TaqMan method.
14 TaqMan assays were vali-
dated by retesting 10% of samples using melt-
ing  curve  analysis  (Light  Cycler,  Roche
Diagnostics) based on G-nucleobase quench-
ing using a 5’-FAM labeled probe (cagccccggc-
cctgttg) spanning the polymorphic locus, in
which the A variant results in a base pair mis-
match. The frequency of the A allele in our
population (0.28) was consistent with previ-
ously published reports, and the population
was  in  Hardy-Weinberg  equilibrium  with
respect to this polymorphism. 
Statistical analysis 
The  clinical  characteristics  and  genotype
frequencies of Black and White patients were
compared using the ˇ
2 test and Fisher’s exact
test,  as  appropriate.  The  Hardy–Weinberg
equilibrium  was  tested  in  both  ethnic
groups.
15 Due to prior evidence,
16 we also test-
ed  for  linkage  disequilibrium  between  the
apoA1  and  apoCIII  C3238G SstI single
nucleotide polymorphisms. The Kaplan-Meier
life table method was used to assess the time
to first coronary end point and the cumulative
event rates for each ethnic group and within
each ethnic group by genotype. The results
were compared using the log-rank test. 
The outcome analysis used Cox multivari-
able  proportional-hazards  regression  with
adjustment for significant clinical covariates
to follow outcomes over time. The outcome
measure was time from enrollment to a first
recurrent  coronary  event  with  follow-up
beginning at the baseline visit two months
after the MI. For regressions, blood marker
variables  were  dichotomized  (highest  vs.
combined  lower  three  quartiles  except  for
apoA1  and  HDL  which  was  lowest  vs. com-
bined  highest  three  quartiles)  as  was  the
apoA-I SNP (AG plus AA vs. GG). The algo-
rithm for choosing model covariates was that
utilized  in  the  parent  study.
13 Multivariable
analyses were performed by initial evaluation
of univariate significance of clinical covari-
ates  (age,  ethnicity,  sex,  diabetes  mellitus,
prior MI being any MI occurring before the MI
of  study  enrollment,  smoking,  BMI,  pul-
monary congestion, hypertension, and cluadi-
cation;  p<0.10),  blood  biomarkers  (apoB,
apoA-I,  total  cholesterol,  triglycerides,  glu-
cose, HDL cholesterol, and insulin; p<0.05),
Table 1. Baseline clinical characteristics.
Characteristics  White  Black 
(n=705)  (n=129) 
Age, y (mean±SD)  60±12  57±11* 
Female gender (%)  22  33* 
MI prior to Index MI (%)  19  22 
Hypertension (%)  39  66* 
Diabetes (%)  15  26* 
Smoking (%)  32.5  34.1 
BMI  27.7±5  29.4±6* 
Q-wave MI as Index MI (%)  50.9  42.6 
LV ejection fraction (%)  47±13  50±11 
Systolic BP (mm/Hg)  118±16  123±16* 
Diastolic BP (mm/Hg)  69±24  72±11* 
Aspirin (%)  83  85 
Statins (%)  34  36 
ACE inhibitors (%)  34  45* 
ß-blockers (%)  79  69* 
Calcium channel blockers (%)  19  32* 
Nitrates (%)  37  47* 
Total Cholesterol (mg/dL)  196±43  196±45 
LDL (mg/dL)  118±36  123±41 
HDL (mg/dL)  39±12  42±12* 
Triglycerides (mg/dL)  208±119  157±87* 
Apo A1 (mg/dL)  119±25  118±26 
Apo B (mg/dL)  122±27  124±32 
Glucose (mg/dL)  101±44  109±46* 
Insulin (IU/mL) 18±24 23±41* 
*p<0.05. MI: myocardial infarction; BP: blood pressure.Article
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and the apoA-I SNP (p<0.05). Multivariable
models were then formulated for main effects
with simultaneous entry of all univariate sig-
nificant covariates. Medication effects (beta
blockers,  aspirin,  calcium  channel  blockers,
diuretics, ACE-inhibitors, statins, other lipid-
lowering drugs; p<0.05) were assessed subse-
quently by individual entry of medications to
multivariable models. Interaction effects were
assessed  by  inclusion  of  interaction  terms
into multivariable models. Analyses were per-
formed  with  Statistica  7.0  (StatSoft,  Inc.,
Tulsa, OK, USA). A 2-sided p<0.05 was used
for declaring statistical significance. 
Results
Clinical characteristics 
Table 1 shows the baseline clinical charac-
teristics in the study population by ethnicity.
Blacks  were  frequently  women,  younger,
hypertensive, diabetic, and had a higher aver-
age body mass index compared to Whites. The
use  of  angiotensin  converting  enzyme
inhibitors,  nitrates,  and  calcium  channel
blockers was higher among Blacks, whereas
beta-blockers  were  administered  more  fre-
quently in Whites. 
Laboratory parameters 
Blacks had higher levels of HDL-C, triglyc-
erides,  glucose,  and  insulin  than  Whites
(Table  1)  but  similar  levels  of  apoA1  and
apoB.  Thirty  percent  of  Whites  and  21%  of
Blacks,  respectively,  were  carriers  of  the
high-risk allele of the apoA1 gene (A/A or A/G)
(Table 2). In Blacks, the presence of the A
allele  was  associated  with  non-significantly
lower  apoA1  (p= 0.59)  (Table  3)  and  in
Whites with higher apoA1 of borderline sig-
nificance (p=0.07). ApoA1 levels were identi-
cal in Blacks and Whites who did not carry the
A allele, whereas among patients with the A
allele  there  was  a trend  for  lower  levels  in
Blacks  compared  with  Whites  (p=0.3).  In
Blacks, the presence of the A allele was associ-
ated with higher apoB (p=0.035) whereas in
Whites the allele was not associated with sig-
nificantly higher apoB (p=0.22). ApoB levels
were  very  similar  in  Blacks  and  Whites
(p=0.88) who did not carry the A allele where-
as among patients with the A allele, there was
a trend for higher levels in Blacks than Whites
(p=0.095). In addition, compared with Whites,
Blacks without the A allele had higher HDL-C
(p=0.014) whereas Blacks and Whites with the
A  allele  had  similar  HDL-C  levels  (p=0.35).
Blacks  and  Whites  without  the  A  allele  had
similar LDL-C levels (p= 0.34) as did Blacks
and Whites with the A allele (p= 0.14). 
End point 
The Kaplan-Meier cumulative probability of
recurrent cardiac events during follow-up for
White  and  Black  patients  by  presence  or
absence of the -75 G>A allele is presented in
Figure 1. In Blacks, those with the A allele
were  more  likely  to  experience  a  recurrent
event (p=0.006). In Whites, those with the A
allele  did  not  have  an  increased  risk
(p=0.348). 
In the entire study population, significant
univariate  Cox  regression  covariates  were
age,  diabetes,  prior  MI,  pulmonary  conges-
tion,  and  claudication  (p<0.10);  and  apoB,
total cholesterol, glucose, and insulin (p< 0.05).
Multivariable Cox regression results adjusted
for these covariates found that only apoB was
significant. To further assess potential effects
of  ethnicity  and  the  A  allele  in  the  entire
study population, these parameters were indi-
vidually and dually forced into the multivari-
able model. Neither was found to be signifi-
cant; however, inclusion in the model of an
Table 2. Frequency of ApoA1 -75G>A genotypes by race.
Overall White Black
ApoA1 Genotype N (n=834) (n=705) (n=129)
G/G (%) 600 72 70.5 79.8
A/G (%) 215 25.8 27 19.4
A/A (%) 19 2 2.5 0.8
ˇ
2 p=0.048
Table 3. Comparison of lipid values by genotype within each racial group.
White Black
G/G A/G or A/A G/G A/G or A/A
ApoA1(mg/dL) 118±24 122±26 118±26 116±28
ApoB (mg/dL) 121±26 124±28 122±32 133±31
HDL(mg/dL) 39±12 39±11 42±12 41±10
LDL(mg/dL) 117±36 120±38 121±41 131±37
Table 4. Baseline clinical characteristics.
Characteristics Blacks with Blacks with Blacks with  Blacks without
AA or AG GG Event Event
(n = 26) (n = 103) (n=27) (n=102)
AA or AG (%)  37 16*
GG (%) 63 84*
Age, y (mean±SD) 57 56.7 60±11 56±11
Female gender % 30 30 30 33
MI prior to Index MI % 20 20 26 21
Hypertension %  60 70 70 65
Diabetes %  20 30 30 25
Smoking % 30 30 26 36
BMI 27.02 29.97* 27±5 30±7*
Q-wave MI as Index Event % 40 40 22 48*
Ejection fraction (% 50.5 49.5 51±13 49±10
Systolic BP (mm/Hg) 122.1 122.4  120±17 124±16
Diastolic BP (mm/Hg)  72.8 72.1 70±12 73±11
Aspirin % 81 85 85 84
Statins % 39 36 26 39
ACE inhibitors % 39 47 33 48
ʲ-blockers % 77 67 74 68
Calcium channel blockers %  46 28* 48 28*
Nitrates %  54 46 63 43*
*p<0.10 for Blacks with or without A allele and for Blacks with or without events.  MI: myocardial infarction; BP: blood pressure.Article
[Heart International 2009; 4:e8] [page 33]
interaction term between ethnicity and the A
allele  revealed  significant  interaction
(p=0.0024). 
In  view  of  the  significant  interaction  of
ethnicity and the A allele, separate multivari-
able Cox models were created for Whites and
Blacks. Cox regression adjusted for univari-
ate significant clinical covariates in Whites
(age, diabetes, prior MI, pulmonary conges-
tion, and claudication) and with simultane-
ous entry of univariate significant laboratory
markers  in  Whites  (apoB,  glucose,  and
insulin) revealed apoB and insulin as signifi-
cant.  When  the  A  allele  was  added  to  this
model and medication use assessed by indi-
vidual entry into the model, significant result-
ing markers included apoB (HR=1.78, 95% CI
1.20-2.65;  p=0.0042)  and  calcium  channel
blockers  (HR=2.53,  95%  CI  1.72-3.72;
p<0.001);  the  A  allele  was  not  significant
(HR=1.12,  95%  CI  0.75-1.67;  p=0.59).  In
Blacks, the only univariate significant clinical
covariate was BMI; while none of the labora-
tory markers including apoB were univariate
significant. Thus, in Blacks with entry of the
A allele into a model adjusted for BMI and
with medication use assessed by individual
entry into the model, only the allele was found
to be significant (HR=2.40, 95% CI 1.07-5.40;
p=0.034). Thus, in Whites apoB predicts risk;
the allele does not. In Blacks, the allele pre-
dicts risk; apoB does not. The allele was not
associated with recurrent events in the total
cohort (HR=1.37, 95% CI 0.95-1.97, p=0.09).
Table  4  outlines  the  distribution  of  clinical
risk  variables  in  Blacks  with  and  without
recurrent coronary events and the A allele. 
The A allele and apoCIII SNPs were found
to be in strong linkage disequilibrium in the
whole population (chi-square=47; p<0.0001)
but  did  not  show  significant  evidence  of
Hardy-Weinberg disequilibrium (“LDA” Java
application as described by Ding, et al.
17) 
Discussion
These data suggest that the A allele for the
ApoA1 gene is associated with an increased
risk  of  recurrent  ischemic  cardiac  events
compared to those without this variant; but
only in Black individuals. Survival free of a
recurrent  event  for  Blacks  with  the  variant
(40%)  was  half  that  for  those  without  the
variant (80%) after 2.5 years of follow-up. In
contrast, survival free of an event was virtual-
ly identical for Whites with and without the
polymorphism. To our knowledge, this is the
first study to document an association of this
polymorphism with recurrent ischemic events
and  to  find  an  association  with  events  in
Blacks but not Whites. The frequency of the
variant differed slightly for Blacks and Whites
but the prevalence overall was 28%; similar to
that noted in prior studies. 
6,9,12,16
The  risk  associated  with  the  A  allele  in
Blacks was not associated with a reduction in
levels of apoA1. The allele’s association with
recurrent events independent of a clear asso-
ciation with apoA1 is puzzling given its tran-
scription  for  apoA1.
18 However,  its  relation-
ship to levels of apoA1 and HDL-C is contro-
versial as exemplified by inconsistencies in
well-designed  studies.
8,9,11,12,16,19-22 The  reason
for inconsistent relationships of the A allele
to  apoA1  levels  between  studies  is  unclear.
We speculate that variation among different
ethnic groups could be a confounder. Danek
et al. suggest that the allele does not directly
affect  the  transcriptional  efficiency  of  the
apoA1 gene, although it may be in linkage dis-
equilibrium with other regulatory sequences
and the combination of these elements may
explain  the  contradictory  results  of  the
allele’s expression.
23 However, a meta-analy-
sis aggregating data from over 3,000 healthy
individuals demonstrated that, despite incon-
sistencies among the study findings regard-
ing the magnitude of the effect, the allele was
overall associated with an increase in apoA1
levels by approximately 5 mg/dL.
24
Compared  to  Blacks  without  the  allele,
those with the allele had significantly higher
levels of apoB. In addition, Blacks without the
allele had higher levels of HDL-C compared
with  Whites,  consistent  with  prior  evi-
dence,
25,26 whereas Blacks and Whites with the
A allele had similar HDL-C levels. A similar
association of the allele with higher levels of
apoB but with no effect on apoA1 has been
described in women enrolled in the Pritikin
Longevity  Center  Program.
6 This  suggests
that the allele may not increase risk in Black
individuals  by  affecting  apoA1  levels,  but
rather, by increasing levels of apoB.
27-29
Commonly encountered SNPs are often not
found  in  both  Black  and  non-Black  popula-
tions.
30 At the same time, individuals from dif-
ferent ethnic groups tend to have fairly con-
sistent biological associations when the same
genetic variants are present among the differ-
ent populations in which they exist, as sug-
gested by an analysis of genetic association
investigations  in  43  diseases.
31 Conversely,
other evidence suggests that genetic variants
can influence risk differently for common dis-
eases among populations with different geo-
graphical  ancestry.
32 Thus,  the  possibility
exists that inconsistent relationships of the
allele  with  serum  lipids  and  risk  among
Blacks and Whites in this study could be due
to  differences  in  genetic  susceptibility
between ethnic groups.
33
Linkage disequilibrium is present between
the allele and the apolipoprotein CIII C3238G
SstI SNP in this study. Impaired functions in
two or more of the multiple genes that control
lipid  metabolism  and  transport  have  been
thought to lead to inherited lipoprotein disor-
ders or atherosclerosis.
34 The apo AI-CIII-AIV
Figure  1.  Survival
free  of  a  recurrent
cardiac  event  in
patients by presence
of  apoA1  polymor-
phisms  (A/A  or
A/G).
Panel A: white patients
Panel B: black patients
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cluster gene is one example of these groups.
The  apoAI gene  is  closely  linked  to,  and
tandemly arranged with, apoCIII and apoAIV
genes within a 15-kb DNA segment on chro-
mosome 11.
16 Evidence also suggests that all
three  genes  are  derived  from  a  common
ancestral precursor
35 and, together, have an
effect  on  apoA1  levels.
16 Polymorphisms  of
apoAIV and apoCIII have also been associated
with dyslipidemia
35 and atherosclerosis, inde-
pendent of plasma lipids
36 and thus could be
implicated  as  risk  factors.  Thus,  given  the
genetic diversity among ethnic groups, it is
possible that the relationship of apoA1 alleles
to  plasma  lipoprotein  levels  and  coronary
heart disease may be modulated by AIV and/or
CIII alleles as they may be in linkage disequi-
librium with the -75 G>A apo A1 allele in cer-
tain populations but not in others
34 or interact
with other genes, and/or with environmental
factors.
9,12,37
In summary, this is the first study to iden-
tify an increased risk for an acute coronary
syndrome  among  Black  individuals  with  a
prior  myocardial  infarction  if  they  have  a
common polymorphism for the apoA1 gene.
Until much more is known about the complex-
ities of the interaction between the -75G>A
single  nucleotide  polymorphism  and  other
genes, these data should be viewed as hypoth-
esis generating. 
Study limitations 
Our results do not provide evidence for a
direct mechanism leading to the adverse out-
come.  Further  investigation  would  be
required to determine if the -75 G>A polymor-
phism influences coronary risk or, instead, is
a  marker  of  other  gene  polymorphisms.
Although we were able to test for the presence
of linkage disequilibrium of the -75 G>A poly-
morphism with apoCIII, we were not able to
do so for apoAIV. Inconsistencies across pop-
ulations may be explained by the approach of
studying single, perhaps non-functional, poly-
morphisms.
38 The findings in this study may
have resulted from chance association. The
possibility also exists that the effect of specif-
ic alleles may depend upon the presence of
environmental  factors  including  smoking,
medications, diet, and physical activity, and
we were able to control for a limited number
of such factors. 
We cannot be certain that a “survival of the
fittest”  bias  in  our  post-MI  cohort  was  not
present.  Black  and  White  patients  with  the 
-75  G>A allele  could  have  died  with  their
index  myocardial  infarction,  resulting  in  a
reduced  effect  of  the  allele  on  the  risk  of
recurrent events amongst survivors. The pro-
portion  of  patients  who  die  at  the  time  of
their first MI is estimated at 15%.
39
The relatively small sample size of Black
individuals relative to Whites limited our abil-
ity to detect a significant difference in apoA1
and HDL-C levels in Blacks with and without
the -75 G>A polymorphism. Also, this is a sin-
gle population study, and these findings need
to be validated in prospective studies involv-
ing larger populations. 
References
1.Ballantyne CM, Nambi V. Apolipoprotein A-
I and high-density lipoprotein: is this the
beginning of the era of noninvasive angio-
plasty? J Am Coll Cardiol 2004;44:1436-8. 
2.Boden WE. High-density lipoprotein cho-
lesterol as an independent risk factor in
cardiovascular disease: assessing the data
from Framingham to the Veterans Affairs
High-Density  Lipoprotein  Intervention
Trial .Am J Cardiol 2000;86(12A):19L-22L. 
3.Shah  PK,  Kaul  S,  Nilsson  J,  Cercek  B.
Exploiting the vascular protective effects
of  high-density  lipoprotein  and  its
apolipoproteins:  an  idea  whose  time  for
testing  is  coming,  part  I.  Circulation
2001;104:2376-83. 
4.Wallenfeldt K, Bokemark L, Wikstrand J, et
al. Apolipoprotein B/apolipoprotein A-I in
relation  to  the  metabolic  syndrome  and
change  in  carotid  artery  intima-media
thickness during 3 years in middle-aged
men. Stroke 2004;35:2248-52. 
5.Sharrett  AR,  Patsch  W,  Sorlie  PD,  et  al.
Associations  of  lipoprotein  cholesterols,
apolipoproteins  A-I  and  B,  and  triglyc-
erides  with  carotid  atherosclerosis  and
coronary  heart  disease.  The  Athero-
sclerosis  Risk  in  Communities  (ARIC)
Study Arterioscler Thromb  1994;14:1098-
104. 
6.Larson IA, Ordovas JM, Barnard JR, et al.
Effects of apolipoprotein A-I genetic varia-
tions  on  plasma  apolipoprotein,  serum
lipoprotein and glucose levels. Clin Genet
2002;61:176-84. 
7.Pagani F, Giudici GA, Baralle FE, Vergani
C. Association of a polymorphism in the
Apo  AI  gene  promoter  with  hyperal-
phalipoproteinemia. Eur J Epidemiol 1992;
8:54-8. 
8.Paul-Hayase H, Rosseneu M, Robinson D,
Van Bervliet JP, Deslypere JP, Humphries
SE. Polymorphisms in the apolipoprotein
(apo) AI-CIII-AIV gene cluster: detection of
genetic variation determining plasma apo
AI, apo CIII and apo AIV concentrations.
Hum Genet 1992;88(4):439-46. 
9.Talmud  PJ,  Ye  S,  Humphries  SE.  Poly-
morphism in the promoter region of the
apolipoprotein AI gene associated with dif-
ferences  in  apolipoprotein  AI  levels:  the
European Atherosclerosis Research Study.
Genet Epidemiol 1994;11:265-80. 
10.Xu CF, Nanjee MN, Savill J, et al. Variation
at  the  apolipoprotein  (apo)  AI-CIII-AIV
gene cluster and apo B gene loci is associ-
ated  with  lipoprotein  and  apolipoprotein
levels in Italian children. Am J Hum Genet
1990;47:429-39. 
11.Barre DE, Guerra R, Verstraete R, Wang Z,
Grundy SM, Cohen JC. Genetic analysis of
a polymorphism in the human apolipopro-
tein A-I gene promoter: effect on plasma
HDL-cholesterol  levels.  J  Lipid  Res
1994;35: 1292-6. 
12.Lopez-Miranda J, Ordovas JM, Espino A, et
al.  Influence  of  mutation  in  human
apolipoprotein A-1 gene promoter on plas-
ma LDL cholesterol response to dietary fat.
Lancet 1994;343:1246-9. 
13.Moss AJ, Goldstein RE, Marder VJ, et al.
Thrombogenic factors and recurrent coro-
nary events. Circulation 1999;99:2517-22. 
14.Moss AJ, Ryan D, Oakes D, et al. Athero-
sclerotic  risk  genotypes  and  recurrent
coronary  events  after  myocardial  infarc-
tion. Am J Cardiol 2005;96:177-82. 
15.Schaid  DJ,  Jacobsen  SJ.  Biased  tests  of
association:  comparisons  of  allele  fre-
quencies  when  departing  from  Hardy-
Weinberg  proportions.  Am  J  Epidemiol
1999;149:706-11. 
16.Xu CF, Angelico F, Del Ben M, Humphries
S. Role of genetic variation at the apo AI-
CIII-AIV gene cluster in determining plas-
ma apo AI levels in boys and girls. Genet
Epidemiol 1993;10:113-22. 
17.Ding K, Zhou K, He F, Shen Y. LDA - a Java-
based  linkage  disequilibrium  analyzer.
Bioinformatics 2003;19:2147-8. 
18.Pownall HJ, Ehnholm C. The unique role
of apolipoprotein A-I in HDL remodeling
and metabolism. Curr Opin Lipidol 2006;
17:209-13. 
19.Sigurdsson G Jr, Gudnason V, Sigurdsson
G, Humphries SE. Interaction between a
polymorphism  of  the  apo  A-I  promoter
region  and  smoking  determines  plasma
levels  of  HDL  and  apo  A-I.  Arterioscler
Thromb 1992;12:1017-22. 
20.Minnich A, DeLangavant G, Lavigne J, et
al. G-->A substitution at position -75 of the
apolipoprotein  A-I  gene  promoter.
Evidence against a direct effect on HDL
cholesterol  levels.  Arterioscler  Thromb
Vasc Biol 1995;15:1740-5. 
21.Kamboh  MI,  Aston  CE,  Nestlerode  CM,
McAllister  AE,  Hamman  RF.  Haplotype
analysis  of  two  APOA1/MspI  polymor-
phisms in relation to plasma levels of apo
A-I  and  HDL-cholesterol.  Atherosclerosis
1996;127:255-62. 
22.Carmena-Ramon RF, Ordovas JM, Ascaso
JF,  Real  J,  Priego  MA,  Carmena  R.
Influence of genetic variation at the apo A-
I gene locus on lipid levels and response to
diet  in  familial  hypercholesterolemia.Article
[Heart International 2009; 4:e8] [page 35]
Atherosclerosis 1998;139:107-13. 
23.Danek GM, Valenti M, Baralle FE, Romano
M. The A/G polymorphism in the -78 posi-
tion  of  the  apolipoprotein  A-I  promoter
does not have a direct effect on transcrip-
tional  efficiency.  Biochim  Biophys  Acta
1998;1398:67-74. 
24.Juo  SH,  Wyszynski  DF,  Beaty  TH,  et  al.
Mild association between the A/G polymor-
phism in the promoter of the apolipopro-
tein A-I gene and apolipoprotein A-I levels:
a  meta-analysis.  Am  J  Med  Genet
1999;8:235-41.
25.Metcalf PA, Sharrett AR, Folsom AR, et al.
African  American-White  differences  in
lipids,  lipoproteins,  and  apolipoproteins,
by educational attainment, among middle-
aged  adults:  the  Atherosclerosis  Risk  in
Communities Study. Am J Epidemiol 1998;
148:750-60. 
26.Donahue RP, Jacobs DR, Sidney S, et al.
Distribution  of  lipoproteins  and
apolipoproteins in young adults The CAR-
DIA Study. Arteriosclerosis 1989;9:656-64. 
27.Lanas F, Avezum A, Bautista LE, et al. Risk
factors for acute myocardial infarction in
Latin  America:  the  INTERHEART  Latin
American  study.  Circulation  2007;115:
1067-74. 
28.Lind  L,  Vessby  B,  Sundstrom  J.  The
apolipoprotein B/AI ratio and the metabol-
ic syndrome independently predict risk for
myocardial infarction in middle-aged men.
Arterioscler  Thromb  Vasc  Biol  2006;26:
406-10. 
29.Barter  PJ,  Ballantyne  CM,  Carmena  R,
Castro Cabezas M, Chapman MJ, Couture
P, et al. Apo B versus cholesterol in esti-
mating cardiovascular risk and in guiding
therapy: Report of the Thirty-Person/Ten-
Country Panel. J Intern Med 2006;259:247-
58. 
30.Bamshad M. Genetic influences on health:
does race matter? JAMA 2005;294:937-46. 
31.Ioannidis  JP,  Ntzani  EE,  Trikalinos  TA.
'Racial' differences in genetic effects for
complex  diseases.  Nat  Genet  2004;36:
1312-8. 
32.Farrer  LA,  Cupples  LA,  Haines  JL,  et  al.
Effects of age, sex, and ethnicity on the
association  between  apolipoprotein  E
genotype and Alzheimer disease. A meta-
analysis.  APOE  and  Alzheimer  Disease
Meta  Analysis  Consortium.  JAMA  1997;
278:1349-56. 
33.Reguero JR, Cubero GI, Batalla A, Alvarez
V, Hevia S, Cortina A, et al. Apolipoprotein
A1 gene polymorphisms and risk of early
coronary disease. Cardiology 1998;90:231-
5. 
34.Hong  SH,  Park  WH,  Lee  CC,  et  al.
Association between genetic variations of
apo  AI-CIII-AIV  cluster  gene  and  hyper-
triglyceridemic subjects. Clin Chem 1997;
43:13-7. 
35.Karathanasis  SK.  Apolipoprotein  multi-
gene  family:  tandem  organization  of
human  apolipoprotein  AI,  CIII,  and  AIV
genes.  Proc  Natl  Acad  Sci  USA  198;82:
6374-8. 
36.Ferns GA, Stocks J, Ritchie C, Galton DJ.
Genetic polymorphisms of apolipoprotein
C-III and insulin in survivors of myocar-
dial infarction. Lancet 1985;2:300-3.
37.Castellano M. Geographic ancestry, angio-
tensinogen gene polymorphism, and car-
diovascular  risk.  Hypertension  2006;48:
562-3. 
38.Lai  CQ,  Parnell  LD,  Ordovas  JM.  The
APOA1/C3/A4/A5 gene cluster, lipid metab-
olism  and  cardiovascular  disease  risk.
Curr Opin Lipidol 2005;16:153-66. 
39.Levy D, Thom TJ. Death rates from coro-
nary disease - progress and a puzzling par-
adox. N Engl J Med 1998;339:915-7. 